|
1. 1. Kaplan HI, Sadock BJ. Synopsis of psychiatry: Behavioral sciences clinical psychiatry. Clin Psychiat. 1988;9(1):63-90. 2. 2. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. [ DOI:10.1093/schbul/13.2.261] [ PMID] 3. 3. Kane JM. Schizophrenia. N Engl J Med. 1996;334(1):34-41. [ DOI:10.1056/NEJM199601043340109] [ PMID] 4. 4. Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA, et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008;69(1):106-13. [ DOI:10.4088/JCP.v69n0114] [ PMID] 5. 5. Remington G. Antipsychotic dosing: still a work in progress. Am J Psychiatry. 2010;167(6):623-5. [ DOI:10.1176/appi.ajp.2010.10030302] [ PMID] 6. 6. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663-7. [ DOI:10.4088/JCP.v64n0607] [ PMID] 7. 7. Grace AA. Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology. 2012;62(3):1342-8. [ DOI:10.1016/j.neuropharm.2011.05.011] [ PMID] [ PMCID] 8. 8. Kelly PJ, Lim LL. Survival analysis for recurrent event data: an application to childhood infectious diseases. Stat Med. 2000;19(1):13-33.
https://doi.org/10.1002/(SICI)1097-0258(20000115)19:1<13::AID-SIM279>3.0.CO;2-5 [ DOI:10.1002/(SICI)1097-0258(20000115)19:13.0.CO;2-5] 9. 9. Gohari MR. [Fraility models for recurrent events with short term dependence]. Tehran Tehran University of Medical Sciences; 2005. [ PMID] 10. 10. Masyn KE. Discrete-time survival mixture analysis for single and recurrent events using latent variables. Los Angeles, California: University of California; 2003. 11. 11. Kleinbaum D, Klein M. Survival analysis: Springer; 1996. [ DOI:10.1007/978-1-4757-2555-1] [ PMID] 12. 12. Lee A, Zhao Y, Yau K, Ng S, editors. Survival mixture modelling of recurrent infections. IASC2008; 2008; Japan: Japanese Society of Computational Statistics. 13. 13. Smith TE, Hull JW, Goodman M, Hedayat-Harris A, Willson DF, Israel LM, et al. The relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder. J Nerv Ment Dis. 1999;187(2):102-8. [ DOI:10.1097/00005053-199902000-00006] [ PMID] 14. 14. Brown ES, Jeffress J, Liggin JD, Garza M, Beard L. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry. 2005;66(6):756-60. [ DOI:10.4088/JCP.v66n0613] [ PMID] 15. 15. Mueser KT, Yarnold PR, Bellack AS. Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta Psychiatr Scand. 1992;85(1):48-55. [ DOI:10.1111/j.1600-0447.1992.tb01441.x] [ PMID] 16. 16. Tondo L, Vazquez GH, Baethge C, Baronessa C, Bolzani L, Koukopoulos A, et al. Comparison of psychotic bipolar disorder, schizoaffective disorder, and schizophrenia: an international, multisite study. Acta Psychiatr Scand. 2016;133(1):34-43. [ DOI:10.1111/acps.12447] [ PMID] |
